Thema: US76029N1063
REPL, US76029N1063
new-york-stock-exchange-1708834_1920.jpg - Foto: THN
Replimune stock advances as TUDRIQEV launch gains traction
Replimune stock follows an early commercial launch for TUDRIQEV in advanced melanoma. The company also reported a narrower quarterly loss.
ad-hoc-news.de, heute 01:35 Uhr
REPL, US76029N1063
Replimune stock: Replimune schedules second-quarter results. ...
Replimune will discuss fiscal second-quarter results on October 28, 2026. Replimune stock posted USD 0.72 loss per share versus USD 0.69 expected.
ad-hoc-news.de, 24.10.26 01:58 Uhr
REPL, US76029N1063
Replimune faces November 5 results: Replimune stock has ...
Replimune's Nasdaq range is USD 1.50 to USD 16.33 on October 20, 2026. Replimune stock costs EUR 10.28 on October 20, 2026 at Lang & Schwarz.
ad-hoc-news.de, 20.10.26 21:09 Uhr
REPL, US76029N1063
Ten analysts set USD 12.00 target for Replimune stock
June 2026 loss was USD 0.72 per share versus USD 0.69 expected. Replimune stock closed at USD 10.86 on October 16, 2026, down 7.57 percent on Nasdaq.
ad-hoc-news.de, 17.10.26 22:23 Uhr
REPL, US76029N1063
Brokerages set USD 12.00 target for Replimune stock
Next earnings are estimated for November 5, 2026. Replimune stock costs EUR 10.56 on October 15, 2026, up 3.78 percent on Nasdaq.
ad-hoc-news.de, 15.10.26 21:50 Uhr
REPL, US76029N1063
Replimune launched TUDRIQEV. Replimune stock fell 1.61 percent. ...
TUDRIQEV trial data showed a 24.20 percent response rate in 140 patients. Replimune stock costs EUR 11.59 on October 8, 2026 after EUR 11.78.
ad-hoc-news.de, 08.10.26 22:56 Uhr
REPL, US76029N1063
Replimune stock gains as share authorization doubles
Replimune stock faces a 300 million share authorization after September 15, 2026. The clinical-stage company reported a USD 297.0 million loss.
ad-hoc-news.de, 23.09.26 08:09 Uhr
Institutional, Confidence
Institutional Confidence Surges in Replimune as Key Drug ...
Replimune US76029N1063
boerse-global.de, 19.02.26 04:21 Uhr
Replimune, Investors
Replimune Investors Await Critical Regulatory and Financial ...
Replimune US76029N1063
boerse-global.de, 02.02.26 13:33 Uhr
Replimune’s, Pivotal
Replimune’s Pivotal Year: Key Catalysts on the 2026 Horizon ...
